Sugi Predict

Sugi Predict / Compounds / SCHEMBL2593351

SCHEMBL2593351

SCHEMBL2593351

CCOC(=O)C(=O)C=C(C)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 3/20 0.48
▸ GLO1 Q04760 1/20 0.48
▸ ALDH1A1 P00352 5/20 0.44
▸ LMNA P02545 3/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ TSHR P16473 1/20 0.42
▸ MAPT P10636 3/20 0.39
▸ CYP2D6 P10635 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ GAA P10253 2/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ MGAM O43451 1/20 0.37
▸ SI P14410 1/20 0.37
▸ MGAM2 Q2M2H8 1/20 0.37
▸ SOAT1 P35610 1/20 0.37
▸ EGLN1 Q9GZT9 1/20 0.36
▸ CYP2C9 P11712 2/20 0.36
▸ HCAR2 Q8TDS4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2593347 1.00 NPSR1 (0.48) NPSR1GLO1ALDH1A1LMNAHSD17B10
SCHEMBL17229336 1.00 NPSR1 (0.48) NPSR1GLO1ALDH1A1LMNAHSD17B10
SCHEMBL23142289 0.87 NPSR1 (0.45) NPSR1GLO1ALDH1A1LMNAHSD17B10
SCHEMBL23142290 0.87 NPSR1 (0.45) NPSR1GLO1ALDH1A1LMNAHSD17B10
SCHEMBL27258480 0.87 NPSR1 (0.45) NPSR1GLO1ALDH1A1LMNAHSD17B10
SCHEMBL4575182 0.84 NPSR1 (0.50) NPSR1GLO1ALDH1A1LMNAHSD17B10
SCHEMBL16883788 0.82 NPSR1 (0.48) NPSR1GLO1ALDH1A1LMNAHSD17B10
SCHEMBL17221431 0.82 ALDH1A1 (0.44) NPSR1GLO1ALDH1A1LMNAHSD17B10
SCHEMBL17221429 0.82 ALDH1A1 (0.44) NPSR1GLO1ALDH1A1LMNAHSD17B10
SCHEMBL17221432 0.82 ALDH1A1 (0.44) NPSR1GLO1ALDH1A1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720067-A1 BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY Recursion Pharmaceuticals, Inc. (US) 2026-04-08 — — EP disclosed
WO-2024246559-A1 BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY EXSCIENTIA AI LIMITED (GB) 2024-12-05 — — WO disclosed
US-10478426-B2 Enhancer of Zeste Homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2019-11-19 — — US disclosed
US-20180207144-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2018-07-26 — — US disclosed
US-9956210-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-3246027-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER GlaxoSmithKline LLC (US) 2017-11-22 — — EP disclosed
US-9649307-B2 Indoles GLAXOSMITHKLINE LLC (US) 2017-05-16 — — US disclosed
US-20170095461-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2017-04-06 — — US disclosed
US-9562041-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2017-02-07 — — US disclosed
US-20160296518-A1 INDOLES GLAXOSMITHKLINE LLC 2016-10-13 — — US disclosed
US-20130345200-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2013-12-26 — — US disclosed
WO-2013173441-A2 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-11-21 — — WO disclosed
EP-2646020-A1 INDOLES GlaxoSmithKline LLC (US) 2013-10-09 — — EP disclosed
US-20130245016-A1 INDOLES GLAXOSMITHKLINE LLC 2013-09-19 — — US disclosed
US-8536179-B2 Indoles GLAXOSMITHKLINE LLC (US) 2013-09-17 — — US disclosed
WO-2013067296-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) 2013-05-10 — — WO disclosed
EP-2566327-A1 INDOLES GlaxoSmithKline LLC (US) 2013-03-13 — — EP disclosed
US-20130053397-A1 INDOLES GLAXOSMITHKLINE LLC 2013-02-28 — — US disclosed
WO-2012075080-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2012-06-07 — — WO disclosed
WO-2011140324-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245016-A1 INDOLES IDO1, IDO2, INMT NPSR1 430/4885GLO1 1843/4885ALDH1A1 38/4885
US-20180207144-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, EZH1, BMI1 NPSR1 4721/4885GLO1 4028/4885ALDH1A1 1092/4885
US-20170095461-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, EZH1, BMI1 NPSR1 4721/4885GLO1 4028/4885ALDH1A1 1092/4885
US-10478426-B2 Enhancer of Zeste Homolog 2 inhibitors EZH2, EZH1, BMI1 NPSR1 4721/4885GLO1 4028/4885ALDH1A1 1092/4885
US-20130345200-A1 INDOLES IDO1, IDO2, INMT NPSR1 430/4885GLO1 1843/4885ALDH1A1 38/4885
US-20130053397-A1 INDOLES IDO1, IDO2, INMT NPSR1 444/4885GLO1 1950/4885ALDH1A1 45/4885
US-20160296518-A1 INDOLES IDO1, IDO2, INMT NPSR1 430/4885GLO1 1843/4885ALDH1A1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.